Literature DB >> 1177455

Chordoma: an analysis of twenty cases treated over a twenty-year span.

I M Ariel, C Verdu.   

Abstract

Chordoma is a recurring malignancy which does not play by the rules. A five-year survival or even a survival of ten years or longer without evidence of tumor cannot assure the surgeon that the malignant growth has been laid to rest. Recurring local episodes as well as metastases may continue to yield to surgery, irradiation, and other forms of treatment for an astonishing length of time. Thus, situations that may be cause for despair in other malignancies are often a challenge for renewed vigorous treatment in chordoma.

Entities:  

Mesh:

Year:  1975        PMID: 1177455     DOI: 10.1002/jso.2930070106

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

1.  Case report 357: chordoma of the fourth lumbar vertebra metastasizing to the thoracic spine and ribs.

Authors:  I F Abdelwahab; P F O'Leary; G C Steiner; A Zwass
Journal:  Skeletal Radiol       Date:  1986       Impact factor: 2.199

2.  The radiologic findings in posterior mediastinal chordoma.

Authors:  B Stratt; R M Steiner
Journal:  Skeletal Radiol       Date:  1980       Impact factor: 2.199

3.  Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis.

Authors:  Ming-Xiang Zou; Guo-Hua Lv; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  Sacral chordoma: can local recurrence after sacrectomy be predicted?

Authors:  S A Hanna; W J S Aston; T W R Briggs; S R Cannon; A Saifuddin
Journal:  Clin Orthop Relat Res       Date:  2008-06-27       Impact factor: 4.176

5.  Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.

Authors:  Ming-Xiang Zou; An-Bo Peng; Guo-Hua Lv; Xiao-Bin Wang; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

Review 6.  Chemotherapy for cranial base tumors.

Authors:  H E Jacob
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Management of sacrococcygeal chordomas.

Authors:  H Atalar; H Selek; Y Yildiz; Y Sağlik
Journal:  Int Orthop       Date:  2006-03-22       Impact factor: 3.075

8.  Total en bloc spondylectomy for L2 chordoma: a case report.

Authors:  Norimitsu Wakao; Shiro Imagama; Zenya Ito; Kei Ando; Kenichi Hirano; Ryoji Tauchi; Akio Muramoto; Hiroki Matsui; Tomohiro Matsumoto; Yukihiro Matsuyama; Naoki Ishiguro
Journal:  Nagoya J Med Sci       Date:  2011-08       Impact factor: 1.131

Review 9.  Primary maxillofacial chordoma: a rare case report and literature review.

Authors:  Yu Cui; Xiang-Yan Cui; Tingting Yu; Zhan-Peng Zhu; Xin Wang
Journal:  J Int Med Res       Date:  2019-08-23       Impact factor: 1.671

10.  The clinical outcome of recurrent sacral chordoma with further surgical treatment.

Authors:  Yongkun Yang; Yuan Li; Weifeng Liu; Hairong Xu; Xiaohui Niu
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.